Boehringer Ingelheim and SBP Group enter partnership to advance next-generation cancer therapies
Partnership provides opportunities to further expand Boehringer Ingelheim’s portfolio of antibody-drug conjugates (ADCs) and T-cell engagers (TcEs)Agreement reinforces Boehringer Ingelheim’s...